A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
aliskiren
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, aliskiren, blood pressure, irbesartan, amlodipine, hydrochlorothiazide
Eligibility Criteria
Inclusion Criteria Patients with essential hypertension Patients with body mass index ≥ 30 kg/m2 Exclusion Criteria Severe hypertension History or evidence of a secondary form of hypertension History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion exclusion criteria also apply.
Sites / Locations
- Novartis Pharmaceuticals
Outcomes
Primary Outcome Measures
Change from baseline in mean sitting diastolic blood pressure after 8 weeks
Secondary Outcome Measures
Change from baseline in mean sitting systolic blood pressure after 8 weeks
Evaluate number mean sitting systolic/diastolic response from baseline to weeks 4 and 8
Mean sitting diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after week 8
Achieve mean sitting blood pressure control target of < 140/90 mmHg after week 8
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00219115
Brief Title
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
Official Title
A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Responsive to HCTZ 25 mg
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
January 2005 (undefined)
Primary Completion Date
March 2006 (Actual)
Study Completion Date
March 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
4. Oversight
5. Study Description
Brief Summary
To evaluate the blood pressure lowering effects of the combination of aliskiren 300 mg and HCTZ 25 mg in obese patients with essential hypertension inadequately treated with HCTZ 25 mg, compared to irbesartan or amlodipine with HCTZ or HCTZ alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, aliskiren, blood pressure, irbesartan, amlodipine, hydrochlorothiazide
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
493 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
aliskiren
Primary Outcome Measure Information:
Title
Change from baseline in mean sitting diastolic blood pressure after 8 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in mean sitting systolic blood pressure after 8 weeks
Title
Evaluate number mean sitting systolic/diastolic response from baseline to weeks 4 and 8
Title
Mean sitting diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after week 8
Title
Achieve mean sitting blood pressure control target of < 140/90 mmHg after week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Patients with essential hypertension
Patients with body mass index ≥ 30 kg/m2
Exclusion Criteria
Severe hypertension
History or evidence of a secondary form of hypertension
History of Hypertensive encephalopathy or cerebrovascular accident.
Other protocol-defined inclusion exclusion criteria also apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Pharmaceuticals
City
East Hanover
State/Province
New Jersey
ZIP/Postal Code
07936
Country
United States
City
Investigative Centers
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
17353513
Citation
Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007 May;49(5):1047-55. doi: 10.1161/HYPERTENSIONAHA.106.084301. Epub 2007 Mar 12.
Results Reference
result
Learn more about this trial
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
We'll reach out to this number within 24 hrs